With over 10,000 Sq.m of fill finish footprint, we can support filling of a wide range of presentations – vials (liquid and lyophilized), pre-filled syringes and autoinjectors.
Our automated fill finish facility efficiently handles high-accuracy, high-viscosity, low-volume protein filing. End-to-end single-use capability enables for faster change over and assurance of cleaning validation.
Our integrated approach to quality management systems enables greater flexibility and leverage pan - organization experience in managing regulatory audits.
Fill Range and Presentation
Fill range is 0.1-100 ml, Vials: 2-100 ml, PFS and auto injector: 0.1-1 ml
Manufacturing Process Flexibility and Formulation
- Manufacturing process flexibility: peristaltic, rotary piston, end-of-end single-use system, sterile filling
- Formulation: liquid, lyophilized
Why Aurigene Pharmaceutical Services?
100+ successful regulatory audits
10+K Sq.m facility footprints
300+ tech operations professionals
Operations supported by digital infrastructure
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Resources
MAY 19, 2023
“Bathtub Chemistry” - Necessity and Aspects of Process Research
Medicine is an essential part of our life. Since ancient time human civilization has been tirelessly engaged to understand the cause and effect of a disease. Sometimes they win and many times they lose. But the story of their curiosity and enthusiasm is a never damping process. On the contrary it increases day by day, year after year.Drug discovery is a vast and ...
Read More
HPAPI Molecule from Development to Market
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....
Read More
Biologics Manufacturing Services
Our manufacturing services cater to both GMP and non-GMP manufacturing for pre-clinical development as well as GMP operation to support clinical or commercial needs for any recombinant proteins expressed in suspension mammalian culture or E. coli. ...
Read More
Development of quick quantification method for muscle injury recovery evaluation in thermal injury mice model
Challenges: The evaluation of Evans Blue Dye (EBD) by fluorescence measurements of cryosections of individual muscle sections, and its quantification by auto fluorescence is a laborious and time-consuming process. Study design: Both sham and thermal injury techniques were followed. The evaluation of EBD was done to assess the effectiveness of two compounds in the...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.